293 related articles for article (PubMed ID: 17408367)
1. Immunization strategies for the prevention of pneumovirus infections.
Bennett N; Ellis J; Bonville C; Rosenberg H; Domachowske J
Expert Rev Vaccines; 2007 Apr; 6(2):169-82. PubMed ID: 17408367
[TBL] [Abstract][Full Text] [Related]
2. Human and bovine respiratory syncytial virus vaccine research and development.
Meyer G; Deplanche M; Schelcher F
Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):191-225. PubMed ID: 17720245
[TBL] [Abstract][Full Text] [Related]
3. Immunopathology of RSV infection: prospects for developing vaccines without this complication.
van Drunen Littel-van den Hurk S; Mapletoft JW; Arsic N; Kovacs-Nolan J
Rev Med Virol; 2007; 17(1):5-34. PubMed ID: 17004293
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
[TBL] [Abstract][Full Text] [Related]
5. Formalin-inactivated bovine RSV vaccine influences antibody levels in bronchoalveolar lavage fluid and disease outcome in experimentally infected calves.
Kalina WV; Woolums AR; Gershwin LJ
Vaccine; 2005 Aug; 23(37):4625-30. PubMed ID: 15967545
[TBL] [Abstract][Full Text] [Related]
6. The distinguishing features of human metapneumovirus and respiratory syncytial virus.
Papenburg J; Boivin G
Rev Med Virol; 2010 Jul; 20(4):245-60. PubMed ID: 20586081
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with respiratory syncytial virus vaccines.
Piedra PA
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S94-9. PubMed ID: 12671459
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic T lymphocyte activity and cytokine expression in calves vaccinated with formalin-inactivated bovine respiratory syncytial virus prior to challenge.
Woolums AR; Gunther RA; McArthur-Vaughan K; Anderson ML; Omlor A; Boyle GA; Friebertshauser KE; McInturff PS; Gershwin LJ
Comp Immunol Microbiol Infect Dis; 2004 Jan; 27(1):57-74. PubMed ID: 14656542
[TBL] [Abstract][Full Text] [Related]
9. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
Ellis J; Gow S; West K; Waldner C; Rhodes C; Mutwiri G; Rosenberg H
J Am Vet Med Assoc; 2007 Jan; 230(2):233-43. PubMed ID: 17223757
[TBL] [Abstract][Full Text] [Related]
10. Development of a PIV-vectored RSV vaccine: preclinical evaluation of safety, toxicity, and enhanced disease and initial clinical testing in healthy adults.
Tang RS; Spaete RR; Thompson MW; MacPhail M; Guzzetta JM; Ryan PC; Reisinger K; Chandler P; Hilty M; Walker RE; Gomez MM; Losonsky GA
Vaccine; 2008 Nov; 26(50):6373-82. PubMed ID: 18822334
[TBL] [Abstract][Full Text] [Related]
11. Bovine respiratory syncytial virus.
Brodersen BW
Vet Clin North Am Food Anim Pract; 2010 Jul; 26(2):323-33. PubMed ID: 20619187
[TBL] [Abstract][Full Text] [Related]
12. The future of respiratory syncytial virus vaccine development.
Polack FP; Karron RA
Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S65-73. PubMed ID: 14730272
[TBL] [Abstract][Full Text] [Related]
13. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis.
Harcourt JL; Karron RA; Tripp RA
J Infect Dis; 2004 Dec; 190(11):1936-40. PubMed ID: 15529257
[TBL] [Abstract][Full Text] [Related]
14. Immunology of bovine respiratory syncytial virus infection of cattle.
Gershwin LJ
Comp Immunol Microbiol Infect Dis; 2012 May; 35(3):253-7. PubMed ID: 22410266
[TBL] [Abstract][Full Text] [Related]
15. Bovine respiratory syncytial virus infection.
Valarcher JF; Taylor G
Vet Res; 2007; 38(2):153-80. PubMed ID: 17257568
[TBL] [Abstract][Full Text] [Related]
16. Respiratory syncytial virus disease mechanisms implicated by human, animal model, and in vitro data facilitate vaccine strategies and new therapeutics.
Moore ML; Peebles RS
Pharmacol Ther; 2006 Nov; 112(2):405-24. PubMed ID: 16820210
[TBL] [Abstract][Full Text] [Related]
17. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
[TBL] [Abstract][Full Text] [Related]
18. Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.
Durbin AP; Karron RA
Clin Infect Dis; 2003 Dec; 37(12):1668-77. PubMed ID: 14689350
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccination against pseudorabies virus and bovine respiratory syncytial virus infections of young animals in the face of maternally derived immunity.
Hamers C; Juillard V; Fischer L
J Comp Pathol; 2007 Jul; 137 Suppl 1():S35-41. PubMed ID: 17553517
[TBL] [Abstract][Full Text] [Related]
20. Respiratory syncytial virus: reverse genetics and vaccine strategies.
Collins PL; Murphy BR
Virology; 2002 May; 296(2):204-11. PubMed ID: 12069519
[No Abstract] [Full Text] [Related]
[Next] [New Search]
